跳至主要内容
临床试验/EUCTR2017-005115-13-GB
EUCTR2017-005115-13-GB进行中(未招募)1 期

A Non-Interventional Study to Monitor the Survival Status of Patients that Discontinued from ISIS 420915-CS2 or ISIS 420915-CS3

Ionis Pharmaceuticals, Inc.0 个研究点目标入组 164 人开始时间: 2018年3月6日最近更新:
适应症

试验速览

阶段
1 期
状态
进行中(未招募)
入组人数
164

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

入选标准

  • 1. Patient or representative must have given written informed consent (signed and dated) and any authorizations required by local law and be able to comply with all study requirements.
  • 2. Patient must be part of the ISIS 420915-CS2 safety population (defined as all patients that received at least 1 dose of Study Drug (placebo or inotersen)) or representative(s) of patient in ISIS 420915-CS2 safety population
  • Are the trial subjects under 18? no
  • Number of subjects for this age range:
  • F.1.2 Adults (18-64 years) yes
  • F.1.2.1 Number of subjects for this age range 82
  • F.1.3 Elderly (>=65 years) yes
  • F.1.3.1 Number of subjects for this age range 82

排除标准

  • 未提供

研究者

相似试验